These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19057796)

  • 1. [FDG-PET in Hodgkin lymphoma].
    Kobe C; Dietlein M; Mauz-Körholz C; Engert A; Borchmann P; Sabri O; Schober O; Schicha H; Kluge R
    Nuklearmedizin; 2008; 47(6):235-8; quiz N75-6. PubMed ID: 19057796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Dietlein M; Franklin J; Markova J; Lohri A; Amthauer H; Klutmann S; Knapp WH; Zijlstra JM; Bockisch A; Weckesser M; Lorenz R; Schreckenberger M; Bares R; Eich HT; Mueller RP; Fuchs M; Borchmann P; Schicha H; Diehl V; Engert A
    Blood; 2008 Nov; 112(10):3989-94. PubMed ID: 18757777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.
    Kobe C; Dietlein M; Kriz J; Furth C; Fuchs M; Borchmann P; Engert A; Eich HT
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1419-28. PubMed ID: 20836677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
    Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
    Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.
    Hutchings M; Kostakoglu L; Zaucha JM; Malkowski B; Biggi A; Danielewicz I; Loft A; Specht L; Lamonica D; Czuczman MS; Nanni C; Zinzani PL; Diehl L; Stern R; Coleman M
    J Clin Oncol; 2014 Sep; 32(25):2705-11. PubMed ID: 25071108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma].
    Kluge R; Körholz D
    Klin Padiatr; 2011 Nov; 223(6):315-9. PubMed ID: 22012607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases.
    Molin D; Hagberg H; Suurküla M; Aström G
    Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779
    [No Abstract]   [Full Text] [Related]  

  • 9. Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging.
    Bair SM; Svoboda J
    PET Clin; 2019 Jul; 14(3):353-368. PubMed ID: 31084775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
    Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Lymphoma Therapy Using (18)F-FDG PET.
    Lowe VJ; Wiseman GA
    J Nucl Med; 2002 Aug; 43(8):1028-30. PubMed ID: 12163627
    [No Abstract]   [Full Text] [Related]  

  • 12. An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.
    Adams HJA; Kwee TC
    Semin Oncol; 2017 Dec; 44(6):404-419. PubMed ID: 29935902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
    Adams HJ; Kwee TC
    Nucl Med Commun; 2016 Dec; 37(12):1333-1334. PubMed ID: 27501435
    [No Abstract]   [Full Text] [Related]  

  • 14. Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: a randomized study caveat.
    Yahalom J
    Leuk Lymphoma; 2007 Sep; 48(9):1667-9. PubMed ID: 17786699
    [No Abstract]   [Full Text] [Related]  

  • 15. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
    Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
    Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.
    Milgrom SA; Dong W; Akhtari M; Smith GL; Pinnix CC; Mawlawi O; Rohren E; Garg N; Chuang H; Yehia ZA; Reddy JP; Gunther JR; Khoury JD; Suki T; Osborne EM; Oki Y; Fanale M; Dabaja BS
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):333-338. PubMed ID: 28068241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.
    Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
    Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
    AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
    Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
    Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.